| Oct 21 |
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
|
| Oct 9 |
Y-mAbs Therapeutics Inc (YMAB) Q2 2024 Earnings Call Highlights: Revenue Growth Driven by ...
|
| Oct 1 |
Y-mAbs to Participate in Upcoming Investor Conferences in October
|
| Sep 25 |
While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate
|
| Sep 6 |
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
|
| Sep 3 |
Y-mAbs to Participate in Upcoming Investor Conferences in September
|
| Aug 13 |
Assessing Y-mAbs Therapeutics: Insights From 5 Financial Analysts
|
| Aug 12 |
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
|
| Aug 12 |
Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
|
| Aug 12 |
Y-mAbs Therapeutics, Inc. (YMAB) Q2 2024 Earnings Call Transcript
|
